Eversept Partners, LP Kal Vista Pharmaceuticals, Inc. Transaction History

Eversept Partners, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 13, 2021	SELL	$14.69 - $42.57 $278,008 - $805,637	-18,925 Closed	0 $0
Q4 2020 Nov 08, 2023	BUY	$12.88 - $19.47 $243,754 - $368,469	18,925 New	18,925 $359,000
Q4 2020 Feb 16, 2021	SELL	$12.88 - $19.47 $1.14 Million - $1.72 Million	-88,375 Reduced 82.36%	18,925 $359,000
Q3 2020 Nov 08, 2023	BUY	$9.83 - $13.99 $171,966 - $244,741	17,494 Added 19.48%	107,300 $1.35 Million
Q3 2020 Nov 13, 2020	BUY	$9.83 - $13.99 $171,966 - $244,741	17,494 Added 19.48%	107,300 $1.35 Million
Q2 2020 Nov 08, 2023	BUY	$6.75 - $12.89 $606,190 - $1.16 Million	89,806 New	89,806 $1.09 Million
Q2 2020 Aug 13, 2020	BUY	$6.75 - $12.89 $606,190 - $1.16 Million	89,806 New	89,806 $1.09 Million

131

53.3M

63.5K

36.6K

Ticker KALV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,602,000
Market Cap $298M
Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Eversept Partners, LP with notifications on news.